|
|
Hungary In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 146 seiten | |||||||||
| Inhalt der Studie: |
Introduction
”Hungary In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017”, a new report by Global Markets Direct, provides key market data on the Hungary In Vitro Diagnosti.....
Introduction ”Hungary In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017”, a new report by Global Markets Direct, provides key market data on the Hungary In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct’s team of industry experts. Scope - Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. - Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017. - 2010 company shares and distribution shares data for each of the seven market categories. - Global corporate-level profiles of key companies operating within the Hungary In Vitro Diagnosticsmarket. - Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Ortho-Clinical Diagnostics Inc., bioMerieux S.A., Beckman Coulter, Inc. and others. Highlights Reasons to buy - Develop business strategies by identifying the key market categories and segments poised for strong growth. - Develop market-entry and market expansion strategies. - Design competition strategies by identifying who-stands-where in the Hungary In Vitro Diagnostics competitive landscape. - Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. - What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize. Report Highlights F. Hoffmann-La Roche Ltd. Siemens Healthcare Abbott Laboratories Ortho-Clinical Diagnostics Inc. bioMerieux S.A. Beckman Coulter, Inc. Bio-Rad Laboratories, Inc. Becton, Dickinson and Company Sysmex Corporation Phadia AB Diatron MI PLC Alere Inc. DiaSorin S.p.A PerkinElmer, Inc. Thermo Fisher Scientific Inc. Qiagen N.V. Gen-Probe Incorporated Grifols, S.A. HORIBA, Ltd. DIAGNOSTICA STAGO, Inc. Life Technologies Corporation Hologic, Inc. Danaher Corporation Immucor, Inc. Cellestis Limited [Studien Infos ausblenden] |
|||||||||||
|
1 Table of Contents 1 Table of Contents 2 1.1 List of Tables 7 1.2 List of Figures 9 2 Introduction 11 2.1 What is This Report About? 11 3 In Vitro Diagnostics In Hungary 12 3.1 In Vitro Diagnostics, Hungary, Overall Revenue ($m), USD Actual, 2003-2017 12 3.2 In Vitro Diagnostics, Hungary, Company share (2009-2010) 18 4 Clinical Chemistry In Hungary 20 4.1 Clinical Chemistry Overall Revenue (2003-2017) 20 4.1.1 Clinical Chemisty Analyzers Revenue (2003-2017) 24 4.1.2 Urine Analysis Revenue (2003-2017) 28 4.2 Clinical Chemistry Distribution Share (2009-2010) 32 4.3 Clinical Chemistry, Hungary, Company share (2009-2010) 33 5 Genetic Testing In Hungary 35 5.1 Genetic Testing Overall Revenue (2003-2017) 35 5.2 Genetic Testing Distribution Share (2009-2010) 39 5.3 Genetic Testing, Hungary, Company share (2009-2010) 40 6 Haematology In Hungary 42 6.1 Haematology Overall Revenue (2003-2017) 42 6.1.1 Haematology Reagents Revenue (2003-2017) 46 6.1.2 Immunohaematology Revenue (2003-2017) 50 6.1.3 Haemostasis Revenue (2003-2017) 54 6.1.4 Haematology Rapid Tests Revenue (2003-2017) 58 6.1.5 Haematology Cell Counters Revenue (2003-2017) 62 6.2 Haematology Distribution Share (2009-2010) 66 6.3 Haematology, Hungary, Company share (2009-2010) 67 7 Histology And Cytology In Hungary 69 7.1 Histology And Cytology Overall Revenue (2003-2017) 69 7.2 Histology And Cytology Distribution Share (2009-2010) 73 7.3 Histology And Cytology, Hungary, Company share (2009-2010) 74 8 Immuno Chemistry In Hungary 76 8.1 Immuno Chemistry Overall Revenue (2003-2017) 76 8.1.1 Disease Specific Immunochemistry Revenue (2003-2017) 80 8.1.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 84 8.1.3 Endocrinology Tests Revenue (2003-2017) 88 8.1.4 Therapeutic Drug Monitoring Revenue (2003-2017) 92 8.1.5 Immunochemistry Analyzers Revenue (2003-2017) 96 8.2 Immuno Chemistry Distribution Share (2009-2010) 100 8.3 Immuno Chemistry, Hungary, Company share (2009-2010) 101 9 Infectious Immunology In Hungary 103 9.1 Infectious Immunology Overall Revenue (2003-2017) 103 9.2 Infectious Immunology Distribution Share (2009-2010) 107 9.3 Infectious Immunology, Hungary, Company share (2009-2010) 108 10 Microbiology Culture In Hungary 110 10.1 Microbiology Culture Overall Revenue (2003-2017) 110 10.1.1 Microbiology Analyzers Revenue (2003-2017) 114 10.2 Microbiology Culture Distribution Share (2009-2010) 118 10.3 Microbiology Culture, Hungary, Company share (2009-2010) 119 11 Overview of Key Companies in Hungary In Vitro Diagnostics Market 120 11.1 F. Hoffmann-La Roche Ltd. 120 11.1.1 Company Overview 120 11.2 Siemens Healthcare 120 11.2.1 Company Overview 120 11.3 Abbott Laboratories 120 11.3.1 Company Overview 120 11.4 Ortho-Clinical Diagnostics Inc. 121 11.4.1 Company Overview 121 11.5 bioMerieux S.A. 121 11.5.1 Company Overview 121 11.6 Beckman Coulter, Inc. 121 11.6.1 Company Overview 121 11.7 Bio-Rad Laboratories, Inc. 122 11.7.1 Company Overview 122 11.8 Becton, Dickinson and Company 122 11.8.1 Company Overview 122 11.9 Sysmex Corporation 122 11.9.1 Company Overview 122 11.10 Phadia AB 123 11.10.1 Company Overview 123 11.11 Diatron MI PLC 123 11.11.1 Company Overview 123 11.12 Alere Inc. 123 11.12.1 Company Overview 123 11.13 DiaSorin S.p.A 124 11.13.1 Company Overview 124 11.14 PerkinElmer, Inc. 124 11.14.1 Company Overview 124 11.15 Thermo Fisher Scientific Inc. 125 11.15.1 Company Overview 125 11.16 Qiagen N.V. 125 11.16.1 Company Overview 125 11.17 Gen-Probe Incorporated 125 11.17.1 Company Overview 125 11.18 Grifols, S.A. 126 11.18.1 Company Overview 126 11.19 HORIBA, Ltd. 126 11.19.1 Company Overview 126 11.20 DIAGNOSTICA STAGO, Inc. 127 11.20.1 Company Overview 127 11.21 Life Technologies Corporation 127 11.21.1 Company Overview 127 11.22 Hologic, Inc. 128 11.22.1 Company Overview 128 11.23 Danaher Corporation 128 11.23.1 Company Overview 128 11.24 Immucor, Inc. 129 11.24.1 Company Overview 129 11.25 Cellestis Limited 129 11.25.1 Company Overview 129 12 Financial Deals Landscape 130 12.1 Partnerships 130 12.1.1 Biofortuna Enters Into Distribution Agreement With Abbott 130 12.1.2 Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics. 131 13 Appendix 132 13.1 Global Markets Direct Research Methodology 132 13.2 Definitions of Markets Covered in the Report 133 13.2.1 In Vitro Diagnostics 133 13.3 Secondary Research 144 13.4 Primary Research 144 13.5 Models 145 13.6 Forecasts 145 13.7 Expert Panel Validation 145 13.8 Currency Conversion 146 13.9 Contact Us 146 13.10 Disclaimer 146 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
1.1 List of Tables Table 1: In Vitro Diagnostics, Hungary, Overall Revenue ($m), USD Actual, 2003-2017 13 Table 2: In Vitro Diagnostics, Hungary, Overall Revenue ($m), USD Actual, Historic, 2003-2010 15 Table 3: In Vitro Diagnostics, Hungary, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 17 Table 4: In Vitro Diagnostics, Hungary, Company share by Revenue ($m), USD Actual, 2009-2010 19 Table 5: Clinical Chemistry, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 21 Table 6: Clinical Chemistry, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 23 Table 7: Clinical Chemisty Analyzers, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 25 Table 8: Clinical Chemisty Analyzers, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 27 Table 9: Urine Analysis, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 29 Table 10: Urine Analysis, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 31 Table 11: Clinical Chemistry, Hungary, Distribution Share by Revenue ($m), USD Actual, 2009-2010 32 Table 12: Clinical Chemistry, Hungary, Company share by Revenue ($m), USD Actual 2009-2010 34 Table 13: Genetic Testing, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 36 Table 14: Genetic Testing, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 38 Table 15: Genetic Testing, Hungary, Distribution Share by Revenue ($m), USD Actual, 2009-2010 39 Table 16: Genetic Testing, Hungary, Company share by Revenue ($m), USD Actual 2009-2010 41 Table 17: Haematology, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 43 Table 18: Haematology, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 45 Table 19: Haematology Reagents, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 47 Table 20: Haematology Reagents, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 49 Table 21: Immunohaematology, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 51 Table 22: Immunohaematology, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 53 Table 23: Haemostasis, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 55 Table 24: Haemostasis, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 57 Table 25: Haematology Rapid Tests, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 59 Table 26: Haematology Rapid Tests, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 61 Table 27: Haematology Cell Counters, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 63 Table 28: Haematology Cell Counters, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 65 Table 29: Haematology, Hungary, Distribution Share by Revenue ($m), USD Actual, 2009-2010 66 Table 30: Haematology, Hungary, Company share by Revenue ($m), USD Actual 2009-2010 68 Table 31: Histology And Cytology, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 70 Table 32: Histology And Cytology, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 72 Table 33: Histology And Cytology, Hungary, Distribution Share by Revenue ($m), USD Actual, 2009-2010 73 Table 34: Histology And Cytology, Hungary, Company share by Revenue ($m), USD Actual 2009-2010 75 Table 35: Immuno Chemistry, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 77 Table 36: Immuno Chemistry, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 79 Table 37: Disease Specific Immunochemistry, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 81 Table 38: Disease Specific Immunochemistry, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 83 Table 39: Drugs of Abuse / Toxicology, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 85 Table 40: Drugs of Abuse / Toxicology, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 87 Table 41: Endocrinology Tests, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 89 Table 42: Endocrinology Tests, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 91 Table 43: Therapeutic Drug Monitoring, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 93 Table 44: Therapeutic Drug Monitoring, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 95 Table 45: Immunochemistry Analyzers, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 97 Table 46: Immunochemistry Analyzers, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 99 Table 47: Immuno Chemistry, Hungary, Distribution Share by Revenue ($m), USD Actual, 2009-2010 100 Table 48: Immuno Chemistry, Hungary, Company share by Revenue ($m), USD Actual 2009-2010 102 Table 49: Infectious Immunology, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 104 Table 50: Infectious Immunology, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 106 Table 51: Infectious Immunology, Hungary, Distribution Share by Revenue ($m), USD Actual, 2009-2010 107 Table 52: Infectious Immunology, Hungary, Company share by Revenue ($m), USD Actual 2009-2010 109 Table 53: Microbiology Culture, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 111 Table 54: Microbiology Culture, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 113 Table 55: Microbiology Analyzers, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 115 Table 56: Microbiology Analyzers, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 117 Table 57: Microbiology Culture, Hungary, Distribution Share by Revenue ($m), USD Actual, 2009-2010 118 Table 58: Microbiology Culture, Hungary, Company share by Revenue ($m), USD Actual 2009-2010 119 Table 59: Biofortuna Enters Into Distribution Agreement With Abbott 130 Table 60: Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics 131 Table 61: USD to Local Currency, Hungary, Average Actual Rate 2003-2010 146 1.2 List of Figures Figure 1: In Vitro Diagnostics, Hungary, Overall Revenue ($m), USD Actual, 2003-2017 12 Figure 2: In Vitro Diagnostics, Hungary, Overall Revenue ($m), USD Actual, Historic, 2003-2010 14 Figure 3: In Vitro Diagnostics, Hungary, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 16 Figure 4: In Vitro Diagnostics, Hungary, Company share (%), 2010 18 Figure 5: Clinical Chemistry, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 20 Figure 6: Clinical Chemistry, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 22 Figure 7: Clinical Chemisty Analyzers, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 24 Figure 8: Clinical Chemisty Analyzers, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 26 Figure 9: Urine Analysis, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 28 Figure 10: Urine Analysis, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 30 Figure 11: Clinical Chemistry, Hungary, Company share (%), 2010 33 Figure 12: Genetic Testing, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 35 Figure 13: Genetic Testing, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 37 Figure 14: Genetic Testing, Hungary, Company share (%), 2010 40 Figure 15: Haematology, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 42 Figure 16: Haematology, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 44 Figure 17: Haematology Reagents, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 46 Figure 18: Haematology Reagents, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 48 Figure 19: Immunohaematology, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 50 Figure 20: Immunohaematology, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 52 Figure 21: Haemostasis, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 54 Figure 22: Haemostasis, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 56 Figure 23: Haematology Rapid Tests, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 58 Figure 24: Haematology Rapid Tests, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 60 Figure 25: Haematology Cell Counters, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 62 Figure 26: Haematology Cell Counters, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 64 Figure 27: Haematology, Hungary, Company share (%), 2010 67 Figure 28: Histology And Cytology, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 69 Figure 29: Histology And Cytology, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 71 Figure 30: Histology And Cytology, Hungary, Company share (%), 2010 74 Figure 31: Immuno Chemistry, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 76 Figure 32: Immuno Chemistry, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 78 Figure 33: Disease Specific Immunochemistry, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 80 Figure 34: Disease Specific Immunochemistry, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 82 Figure 35: Drugs of Abuse / Toxicology, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 84 Figure 36: Drugs of Abuse / Toxicology, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 86 Figure 37: Endocrinology Tests, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 88 Figure 38: Endocrinology Tests, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 90 Figure 39: Therapeutic Drug Monitoring, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 92 Figure 40: Therapeutic Drug Monitoring, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 94 Figure 41: Immunochemistry Analyzers, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 96 Figure 42: Immunochemistry Analyzers, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 98 Figure 43: Immuno Chemistry, Hungary, Company share (%), 2010 101 Figure 44: Infectious Immunology, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 103 Figure 45: Infectious Immunology, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 105 Figure 46: Infectious Immunology, Hungary, Company share (%), 2010 108 Figure 47: Microbiology Culture, Hungary, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 110 Figure 48: Microbiology Culture, Hungary, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 112 Figure 49: Microbiology Analyzers, Hungary, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 114 Figure 50: Microbiology Analyzers, Hungary, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 116 Figure 51: Microbiology Culture, Hungary, Company share (%), 2010 119 Figure 52: Global Markets Direct Methodology 132 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||


